| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10.24 | Celldex Therapeutics' Barzolvolimab Meets Phase 2 Study Endpoints For Chronic Inducible Urticaria | 704 | AFX News | WASHINGTON (dpa-AFX) - Celldex Therapeutics Inc. (CLDX) announced that barzolvolimab met all primary and secondary endpoints with high statistical significance in a positive Phase 2 study targeting... ► Artikel lesen | |
| 27.10.24 | Novartis Announces Promising 12-Month Results For Fabhalta In C3 Glomerulopathy | 874 | AFX News | BASEL (dpa-AFX) - Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at the American Society of Nephrology or ASN Kidney Week 2024. The results showed that patients with... ► Artikel lesen | |
| 27.10.24 | Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy | 744 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 771 |
| EVOTEC | 420 |
| NOVO NORDISK | 396 |
| TESLA | 369 |
| RHEINMETALL | 324 |
| BYD | 307 |
| RENK GROUP | 208 |
| DEUTZ | 205 |
| BAYER | 177 |
| TUI | 165 |
| STEYR MOTORS | 164 |
| BASF | 162 |
| APPLE | 158 |
| VOLKSWAGEN | 158 |
| NETFLIX | 157 |
| PLUG POWER | 147 |
| ALMONTY | 145 |
| AMAZON | 143 |
| UNITEDHEALTH | 137 |
| COMMERZBANK | 136 |
| NEL | 136 |
| XIAOMI | 136 |
| DEUTSCHE BANK | 131 |
| E.ON | 130 |
| MERCEDES-BENZ | 129 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
